Last checked at 13 Jan 2014 16:45
For immediate release | 13 January 2014 |
Futura Medical plc
("Futura" or "the Company")
Remuneration of Non-Executive Directors
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces the issue of 52,092 new ordinary shares in respect of the 2013 remuneration of its Non-Executive Directors.
In accordance with the announcement of 2 January 2013, Non-Executive Directors receive approximately 30 per cent of their remuneration in the Company's ordinary shares. For 2013 these were issued at 58.15 pence per share, being the average closing mid-price of the 10 trading days prior to the 2 January 2013. The 52,092 new ordinary shares shall rank pari passu with the existing issued ordinary shares of the Company and have been issued as follows:
Director | Number of ordinary shares issued for 2013 remuneration | Total number of ordinary shares held | Percentage of the Company's issued share capital |
John Clarke | 33,132 | 53,537 | 0.07% |
Jonathan Freeman | 8,118 | 14,920 | 0.02% |
Lisa Arnold | 10,842 | 17,500 | 0.02% |
Application has been made to the London Stock Exchange and it is anticipated that trading of the new ordinary shares will commence on AIM at 8:00am on 17 January 2014.
For the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 77,809,576 ordinary shares of 0.2p each, with one voting right per share. There are no shares held in treasury. The total number of voting rights in the Company is therefore 77,809,576.
The above figure of 77,809,576 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company, under the Disclosure and Transparency Rules.
The Company has received notification that Lisa Arnold, a non-executive director of the Company, has today transferred 6,658 shares in the Company from certificated form in her name into her account at Hargreaves Lansdown.
No disposal has taken place for the purposes of the AIM Rules for Companies. Ms Arnold's aggregate beneficial holding remains unchanged at 17,500 ordinary shares.
The shares element of the 2014 year's Non-Executive Directors' remuneration will be awarded at 63.25 pence per share, being the average closing mid-price of the last 10 trading days of 2013. The Non-Executive Directors will receive the shares at the end of the 2014 financial year.
Full details of Non-Executive Directors' remuneration will be included in the Company's Annual Report & Accounts.
For any further information please contact:
Futura Medical plc | + 44 (0) 1483 685 670 |
James Barder, Chief Executive Officer Mail to: James.Barder@futuramedical.com | www.futuramedical.com |
Cenkos Securities plc | |
Bobbie Hilliam | +44 (0) 20 7397 8900 |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes to editors:
About Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com